Introduction
Multiple ongoing clinical trials are investigating the effects of anti-programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immunotherapy, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] including in colorectal cancer (CRC). 11 Although CRC generally shows a very poor response to anti-PD-1/PD-L1 immunotherapy, definite clinical responses have been observed in mismatch repair-deficient or high microsatellite instability (MSI-H) CRCs, 12, 13 which constitute 4-20% of sporadic CRCs. [14] [15] [16] MSI is caused by dysfunction or deficiency of repair proteins such as MLH1, MSH2, MSH6 and PMS2; it can be inherited through germline mutations or may be sporadic when caused by MLH1 promotor hypermethylation or biallelic mutations in the repair proteins. 11 It is thus plausible that MSI-H CRCs would respond well to anti-PD-1/PD-L1 therapy, as these tumors exhibit high numbers of tumor-infiltrating lymphocytes, presumably in response to a milieu of neopeptides generated by mutations caused by defective mismatch-repair proteins. 17 However, the cell types that are the prime targets of immunotherapy have not been definitively identified. Llosa et al. reported that large numbers of PD-L1-positive myeloid cells such as macrophages and tumor-infiltrating lymphocytes are observed at the invasive front (i.e., the interface between the tumor cells and stroma in the advancing tumor) of mismatch repair-deficient CRCs. 18 In our study, we evaluated PD-L1 expression on tumor and stromal myeloid cells at the invasive front in surgically resected MSI-H and microsatellite-stable (MSS) CRCs, and determined the localizations of PD-L1, PD-1, cluster of differentiation (CD)8 and CD68-positive cells using immunohistochemical and immunofluorescence staining. These results may have clinical implications for the selection of therapeutic target cells for immune checkpoint therapy and for identifying the cells that are associated with immune escape at the invasive front, both of which are critical to the development of novel combination therapies.
Material and Methods

Ethical considerations
Our study was approved by the institutional review board of Kyushu University Fukuoka, Japan (permission number: ) and conformed to the tenets of the Declaration of Helsinki. Informed consent was waived by the institutional review board owing to the retrospective nature of the study.
Patients and specimens
We retrospectively assessed 499 patients who underwent surgical resection of primary CRC between January 1994 and December 2015 at the Department of Surgery and Sciences, Graduate School of Kyushu University Hospital. The histological diagnoses were based on the 2015 World Health Organization classification. Pathological staging was performed according to the Union for International Cancer Control TNM classification (8th edition). The clinicopathological data collected included the patients' sex and age at surgery; the tumors' laterality, histological type and pathological depth of invasion; lymph node metastasis; lymphatic invasion; vascular invasion and pathological stage. Overall survival (OS) data were also collected; factors affecting OS were determined by multiple logistic-regression analysis. None of the patients had received neoadjuvant therapy.
MSI analysis and case selection
MSI status was assessed using fluorescent-labeled primers and an automated DNA sequencer, as described previously. [19] [20] [21] [22] Briefly, we amplified the microsatellite domain from cancerous and normal tissues using polymerase chain reaction. The fluorescent-labeled polymerase chain reaction product was loaded onto an ABI 310 sequencer (Applied Biosystems, Foster City, CA), and the data were analyzed using GeneScan software (Thermo Fisher Scientific, Waltham, MA). MSI was determined based on the analysis of 5 reference markers (D2S123, D5S107, D10S197, D11S904 and D13S175). MSI-H was defined as a replication error in at least 2 markers, low MSI (MSI-L) was defined as a replication error in a single marker, and MSS was defined as no replication errors among the reference markers. Patients with MSS or MSI-L were combined into the MSS group. The MSI status was determined for all patients; 48 were classified as MSI-H and the remaining 451 as MSS. Significant factors (sex and pathological stage) were used for propensity score analysis; as a result, 46 patients from each of the MSI-H and MSS groups were selected. Ultimately, 36 MSI-H and 37 MSS patients were included in the final histological analysis (Supplemental Fig. S1 ).
Immunohistochemistry
Immunohistochemistry was performed on 4-mm-thick, formalin-fixed, paraffin-embedded tissue sections with the following antibodies according to the manufacturers' recommendations: PD-L1 (clone SP142, 1:100 dilution; Spring Bioscience, Pleasanton, CA), PD-1 (clone D4W2J, 1:200 dilution; Cell Signaling Technology, MA), CD8 (clone C8/144B, 1:100 dilution; Dako, Carpinteria, CA) and CD68 (clone KP1, 1:400 dilution, Dako). The sections were incubated with 3,3 0 -diaminobenzidine tetrahydrochloride solution for 3-4 min. The sections were then counterstained with hematoxylin, dehydrated and mounted under coverslips. Microscopic interpretation of each immunohistochemical marker was performed independently by 3 investigators (S.K., Y.N. and S.O.) using the following criteria: (1) PD-L1 was considered positive in tumor cells (PD-L1 [T]) when membranous staining was evident in 1% or more of these cells; likewise, PD-L1 was considered positive in tumor-infiltrating myeloid cells in the stroma (PD-L1 [I]) when membranous staining was observed in 1% or more of these cells. The 1% cutoff values were based on a previous study by Takada et al. 23 We also constructed a histogram based on the pro- Immunotherapy is reportedly effective in colorectal cancers (CRCs) with high microsatellite instability (MSI-H); however, the specific cell types that respond to immune checkpoint therapy remain unclear. Our study examined the expression of programmed cell death-ligand 1 (PD-L1) and related proteins in MSI-H and microsatellite-stable CRCs to investigate the immune microenvironment at the tumor's invasive front. The data suggest that CRC cases with both PD-L1-positive tumor cells and M2-type tumor-associated macrophages are associated with tumor invasion and immune escape at the invasive front. Thus, PD-L1-positive M2-type macrophages at the invasive front may be a potential therapeutic target for immune checkpoint inhibitors.
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Solutions, Waltham, MA) in both the central part and invasive front of each tumor. Similarly, the numbers of PD-1-, CD8-and CD68-positive cells were manually counted under 3400 magnification in 3-5 high-powered fields in the central part and invasive front of each tumor. The mean densities of PD-1-, CD8-and CD68-positive cells were calculated.
Immunofluorescence staining
Immunofluorescence staining for PD-L1/cytokeratin, PD-L1/ CD68, PD-L1/CD163 and PD-1/CD8 was performed using pan-CK AE1/AE3 (clone MAB3412, 1:100 dilution; Dako) and CD163 (clone 10D6, 1:100 dilution; Leica Biosystems, Newcastle upon Tyne UK) antibodies according to their manufacturers' recommendations. Secondary antibodies conjugated to Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 568 goat anti-rabbit IgG (Life Technologies, Carlsbad, CA) were used at 1:400 dilutions. After washing in phosphate-buffered solution, the nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole and the coverslips were mounted in ProLong Gold Antifade Mountant (Thermo Fisher Scientific). Fluorescence images were captured using a Nikon A1R confocal imaging system including an A1-DUS spectral detector unit controlled by the Nikon NIS Elements software (Nikon, Tokyo, Japan). The objective lens was an oil immersion PlanApo 603 NA 1.40 lens (Nikon). Background autofluorescence was eliminated using a spectral unmixing method.
Statistical analysis
Multiple logistic regression analysis and propensity score matching were performed using SAS software version 9.3 (SAS Institute, Inc., Cary, NC). The relationships between various clinicopathological factors and PD-L1 expression were analyzed using the v 2 or Fisher's exact test. The localizations of PD-L1-, PD-1-, CD8-and CD68-positive cells were analyzed using Student's t-test. Differences were considered significant at p < 0.05. These statistical analyses were performed using JMP (version 13; SAS Institute, Inc., Cary, NC).
Results
Associations between PD-L1 expression and clinicopathological characteristics in MSI-H and MSS CRCs
Thirty-six MSI-H and 37 MSS CRCs were included in our study. There were significant differences in the clinicopathological features according to the MSI status. Poorly differentiated adenocarcinoma and right-sided tumors were observed more frequently in the MSI-H group than in the MSS group (p < 0.001 and p < 0.01, respectively) (Supplemental Table  S1 ). Representative PD-L1 staining images are shown in Figures 1a-1f; PD-L1 was expressed on tumor cells and, as reported previously, 24 even more strongly on stromal myeloid cells such as macrophages, tumor-infiltrating lymphocytes and dendritic cells. The proportions of PD-L1-positive cells to the total tumor cells and stromal myeloid cells in our study patients are shown in Figure 1g . Overall, 42 of 73 CRCs (57.5%) were positive for PD-L1 (Fig. 1g) . The mean percentage of PD-L1-positive cells relative to the total tumor and stromal cells was significantly higher in MSI-H than in MSS CRCs (12.2% vs. 1.8%; p < 0.001). PD-L1 (T) positivity was detected in only 2 of 37 MSS CRCs (5.4%) and in 13 of 36 in MSI-H CRCs (36.1%). PD-L1 (T)-positive MSI-H CRCs significantly correlated with poor differentiation, lymphatic invasion and vascular invasion (p 5 0.049, p 5 0.049 and p 5 0.03, respectively) ( Table 1, Supplemental Table S2 ). PD-L1 (I) positivity was detected in 10 of 37 in MSS CRCs (27%) and in 26 of 36 MSI-H CRCs (72.2%). PD-L1 (I) expression in MSI-H CRCs significantly correlated with early-stage disease (p 5 0.03) ( Table 2, Supplemental Table S3 ). We also analyzed the correlation between PD-L1 expression and budding grade; the latter was evaluated using the clinical practice guideline of the Japan Society of Clinical Oncology 25 Abbreviations: m, mucosa; sm, submucosa; mp, muscularis propria; ss, subserosa; se (a), serosa (adventitia); si (ai), invasion of adjacent structures; mode, moderately differentiated type. The data are presented as n (%).
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We further analyzed the PD-L1 expression on tumor cells and TAMs at the invasive front using immunofluorescence and high-resolution confocal microscopy in representative MSI-H and MSS tumor samples. In the MSI-H CRC samples, PD-L1 was predominantly expressed on CD68-positive macrophages infiltrating the stroma at the invasive front. PD-L1 was particularly expressed on CD163-positive macrophages (Figs. 4a and 4b ), which were CD45-positive hematopoietic cells (data not shown). These findings suggest that PD-L1-positive M2 type macrophages highly infiltrate the invasive front of MSI-H CRCs. In contrast, PD-L1 was not expressed on CD68-and CD163-positive macrophages in MSS CRC samples (Figs. 4c and 4d) . Both PD-L1 and cytokeratin were expressed at the invasive front of MSI-H tumors (Fig. 4e) . Additional immunofluorescence and high-resolution confocal microscopy images are shown in Supplemental Figure S3 . Table S4 ).
Discussion
Our study provided in-depth data concerning the clinicopathological associations of PD-L1 expression on tumor cells and on stromal myeloid cells in MSI-H and MSS CRCs. In addition, our analysis of the localization of PD-L1-, PD-1-, CD8-and CD68-positive cells in MSI-H and MSS CRCs suggested that PD-L1 expression is predominant on M2-type macrophages at the invasive front of MSI-H CRCs. Llosa et al. suggested that immune checkpoint protein expression in tumor-infiltrating lymphocytes, stroma and the invasive front may explain these tumors' ability to evade destruction by the patient's immune system. 18 Interestingly, PD-L1 expression appears to be predominant on infiltrating myeloid cells rather than on the tumor cells at the invasive front in patients with CRC.
Studies that evaluate PD-L1 expression separately on tumor cells vs. stromal myeloid cells are rare. 24 Our study yielded 3 key findings. First, PD-L1 (T) expression in MSI-H CRCs significantly correlated with poor differentiation, lymphatic invasion and vascular invasion. These results indicate that PD-L1 expression on tumor cells is associated with aggressive histological features. 29, 30 Rosenbaum et al. suggested that PD-L1 expression on tumor cells is associated with MSI, BRAF mutation and a medullary morphology (a poorly differentiated CRC subtype); our results are partially consistent with theirs.
Second, we found that PD-L1 (I) expression was significantly correlated with early-stage and high (grade 2/3) budding. In early-stage MSI-H CRCs, lymphoplasmacytic infiltration was frequently observed in the stroma. Llosa [32] [33] [34] [35] Our previous study reported that transforming growth factor-b1 induced the expression of zinc finger E-box binding homeobox 1 (ZEB1), a transcription factor related to EMT, and upregulated PD-L1 expression at the invasive front in esophageal cancer. 35 Therefore, further investigation of the association between EMT and PD-L1 upregulation in CRCs is warranted. Furthermore, PD-L1 expression was predominantly observed on M2-type macrophages at the invasive front of MSI-H CRCs in our study. Macrophages are essential immune cells that play a critical role in carcinogenesis and tumor progression, 36 and can be polarized in either of 2 distinct states upon activation: the classically activated (M1) phenotype and the alternatively activated (M2) phenotype. 37, 38 Interleukin (IL)-4, IL-10 and IL-13 polarize macrophages toward the M2 phenotype, which show more phagocytic activity and carcinogenic function, high expression of IL-10 and arginase, and low expression of major histocompatibility complex class II and IL-12. 39 Most M2 macrophages are considered TAMs, and function to promote tumor angiogenesis and metastasis. 40 Our data suggest that PD-L1-positive M2-type macrophages are highly present at the invasive front of MSI-H CRCs. Interestingly, only M2-type macrophages that present at the boundary between the tumor cells and stroma at the invasive front expressed PD-L1; those on the distal part of the stromal side did not. These results imply that PD-L1-positive tumor cells and PD-L1-positive M2-type TAMs may contribute to tumor invasion and immune escape at the invasive front of MSI-H CRCs. Hence, PD-L1-positive M2-type macrophages may represent therapeutic targets for immune checkpoint inhibitors in addition to PD-L1-positive tumor cells. Finally, there was a significant correlation between the expression of PD-1 and PD-L1 (I) at the tumor's invasive front. Based on the observed association between PD-L1 expression and frequent tumor-infiltrating lymphocytes, including PD-1-/CD8-positive lymphocytes, our findings suggest that the upregulation of PD-L1 at the invasive front of MSI-H CRCs is due to an adaptive immune response.
There are some limitations to our study. It was difficult to determine the expression of PD-L1 on tumor cells; thus, different results may have been obtained if other anti-PD-L1 antibodies were used. The appropriate antibodies and cutoff values for the assessment of PD-L1 expression in CRCs have not yet been established, and standardized methods to evaluate PD-L1 expression are therefore required. Moreover, the possibility of patient selection bias due to our study's retrospective nature cannot be ruled out. However, our detailed analysis provides a greater understanding of MSI-H and MSS CRCs, as well as clues for more effective combinations of existing standard treatments and immune checkpoint inhibitors. Such improved regimens can lead to a greater success with immunotherapy in all patients with CRC.
In summary, our data suggest that CRCs with both PD-L1-positive tumor cells and M2-type TAMs are associated with increased risks of tumor invasion and immune escape at the invasive front. PD-L1-positive M2-type macrophages at the invasive front may therefore serve as a potential therapeutic target for immune checkpoint inhibitors.
